Disinfectant caps in vitro effectiveness

Sara Giordana Rimoldi1, Leyla La Cava2, Chiara Palladino3

  • 1Microbiology, Virology and Bioemergency Unit, ASST Fatebenefratelli Sacco, Milan, Italy.

Le Infezioni in Medicina
|December 11, 2023
PubMed

Insights

Disinfectant caps (DCs) effectively prevent catheter-related bloodstream infections (CRBSIs) by maintaining catheter lumen sterility. Both tested brands showed comparable efficacy, supporting their routine use in healthcare settings.

Area of Science:

  • Infection Control
  • Medical Device Efficacy
  • Antimicrobial Technology

Background:

  • Catheter-related bloodstream infections (CRBSIs) pose significant risks to hospitalized patients.
  • Disinfectant caps (DCs) are increasingly recognized for their potential to reduce CRBSI rates.
  • Evaluating the efficacy of different DC manufacturers is crucial for infection prevention strategies.

Purpose of the Study:

  • To assess the in-vitro antiseptic efficacy of disinfectant caps (DCs) from two manufacturers.
  • To compare the effectiveness of these DCs under baseline and stress conditions.
  • To determine if significant differences exist between the two tested DC products.

Main Methods:

  • An in-vitro model was used to test thirteen different microorganisms.
  • Disinfectant effectiveness was evaluated with DCs on needle-free connectors (NFCs) and directly on catheter hubs.
  • Bacterial growth was assessed after incubation periods of 90 and 180 minutes.

Main Results:

  • Both DC manufacturers demonstrated effectiveness in baseline tests across fourteen assays.
  • Under stress conditions, significant bacterial load (Serratia marcescens) was observed only with one product (ICU Medical™) at specific time points.
  • Low bacterial loads for MDR Acinetobacter baumannii were noted for the other product (BD PureHub™).

Conclusions:

  • Results align with existing data for BD PureHub™ and provide new insights for ICU Medical™.
  • No significant difference in effectiveness was found between the two DC brands tested.
  • The routine use of DCs with NFCs is supported to reduce CRBSI incidence as part of comprehensive infection control bundles.
Abstract